Medicon Valley Alliance and IQVIA would like to welcome you to a Good Morning Meeting 5th of September 2024.
Real world evidence (RWE) is becoming increasingly important throughout the product lifecycle. Once considered optional, it is now a necessity. With increasing focus from both regulatory and market access stakeholders, RWE requirements need to be planned for early in the development lifecycle to maximise both access for patients and return on investment.
Rather than replacing clinical trials, RWE can complement and enhance your clinical development and if considered early can reduce overall costs. RWE offers the opportunity for more comprehensive information, better decision making, de-risking and accelerating clinical program timelines and enhances representativeness. Key to the success of a RWE strategy is understanding the different stakeholder needs and requirements, and how these can be best met through a variety of approaches.
Join us for this Good Morning Meeting where IQVIA, recognised as the leader in Real World Evidence and Real World data solutions (as determined by independent research on RWE/Medical Affairs Market landscape) will share insights and learning on RWE strategies across the product lifecycle, sources of information, pitfalls, recent decisions informed by RWE and RWE opportunities for value creation.
Date: Thursday, 5th of September, 2024
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | IQVIA introduction Ditlev Moltke, Commercial Director, IQVIA |
| 9:10 | RWE to maximise asset value Emma Chaffin, Senior Client Partner, IQVIA |
| 9:40 | Standing out using patient outcomes Livia Lai, Senior Principal, IQVIA |
| 10:10 | Q&A Session |
| 10:30 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Ditlev Moltke, Commercial Director, IQVIA
Ditlev Moltke is heading IQVIA the commercial engagements of IQVIA in Nordics. He has been with IQVIA for 9 years, and uses his long background from health data orchestration and commercial consulting to secure innovative solutions in partnership with our clients. |
 |
Emma Chaffin, Senior Client Partner, IQVIA
Emma has over 25 years’ experience across the life sciences industry, predominantly in consulting, small-mid size pharma and biotech.A pharmacist by training, Emma spent 5 years working in clinical services at large teaching Trusts in the UK before making a move to IQVIA where she headed up the RWE research team. From there, she moved into commercial consulting as a Client Partner with IQVIA, delivering multi-country, multi-business line consulting engagements, predominantly to top 10 pharma clients.Emma then moved to a niche market access consultancy where she was instrumental in building their EU practice at a time when market access was embryonic across the EU. Emma then returned to IQVIA as a Client Principal. During this time, she also completed an Executive MBA with Ashridge Business School. Emma then transitioned to various UK and EU leadership roles within the pharmaceutical and biotech industry. Always in the commercial space and with increasing levels of seniority and geographical reach, her roles covered CNS, dermatology, anaemia and immunology. Her experience ranges from mass market therapeutics to orphan products. Geographically, Emma has worked across Europe, Middle-East, Africa, Canada and Australia. More recently, in her General Management roles, she has had full P&L responsibility for teams of up to 100 across the full operational spectrum, including medical and support functions. Emma’s experience spans the full clinical development and commercial life cycle. She has built commercial biotech organisations from the ground up 3 times; once in an incredibly resource constrained environment and supported one organisation through a $50m IPO, the largest biotech IPO in that particular year. Her most recent role was as Vice President Commercial for Galapagos where she oversaw the launch of their first molecule in 2 indications across 5 countries, delivering 200% versus target in launch year (during COVID and in the initial post-Brexit period). Emma is working for IQVIA 4 days a week, on the 5th day of the week she provides fractional CCO support to 3 clinical-stage biotechs.
|
 |
Livia Lai, Senior Principal, IQVIA
Livia is a Senior Principal at IQVIA’s Patient Centered Solutions (PCS) team. Her team specializes in supporting sponsors in developing Clinical Outcome Assessment (COA) strategy in drug development program and generation of patient experience data to support medical strategy. In her current role, Livia delivers patient-centric strategic services for clients including clinical development strategy and protocol design, COA instrument design and development, regulatory and payer strategy for patient-centered claims and endpoints, and evidence communication. Livia has supported various emerging and established biopharma companies in developing and validating COA instruments as key endpoints in clinical trials, across rare disease, oncology, immunology and cardiovascular and metabolic indications. Prior joining the PCS team, Livia worked in strategy consulting, across market access and HTA evidence strategy, and market opportunity assessment and forecasting. She is a co-author in a number of publication on the use and impact of patient reported outcomes (PROs) in HTA, including a chapter in the PCS book: Using Patient Experience Data to Evaluate Medical Interventions. Before joining IQVIA, she worked as a postdoctoral research fellow at the University of Oxford, and UK-China technology transfer and business partnering. Livia holds a PhD in biophysics and a BSc in biochemistry from Imperial College London.
|
| Organized by | In collaboration with |
 |
 |